{"product_id":"iconplc-five-forces-analysis","title":"ICON (Ireland) Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eICON (Ireland) operates in a high-stakes CRO market where client bargaining power, regulatory scrutiny, and technological differentiation shape margins and growth prospects; supplier concentration and potential biotech insourcings pose moderate threats while barriers to entry remain significant due to scale and regulatory know-how.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface—unlock the full Porter's Five Forces Analysis to explore ICON (Ireland)’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScarcity of Specialized Clinical Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe global shortage of experienced clinical research associates and data scientists remained acute in late 2025, with an estimated 18% annual shortfall in skilled CRA roles and a 22% gap for advanced clinical data scientists, boosting supplier bargaining power; ICON (Ireland) relies on these hires to run decentralized trials across 60+ jurisdictions and thus faces rising labor costs—ICON reported a 7% rise in personnel spend in FY2024—forcing higher pay and aggressive recruitment to protect service quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on Investigative Site Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical trial sites—hospitals and private clinics—are essential suppliers of patient access and data collection; in 2024 sites provided over 80% of enrollment for global Phase II–III trials, giving them clear bargaining leverage.\u003c\/p\u003e\n\u003cp\u003eICON’s Accellacare network of ~1,200 sites (2025 internal report) reduces dependence, but ICON still relies on third-party sites for ~40–50% of large global studies.\u003c\/p\u003e\n\u003cp\u003eSites holding unique access to rare-disease cohorts or niche oncology expertise command premium rates and stricter contract terms, especially for orphan drug trials where patient pools under 10,000 increase site negotiating power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Specialized Technology Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs trials go digital, ICON depends on niche electronic data capture and wearable-integration vendors whose specialized software is hard to swap mid-study, risking data integrity; such suppliers can extract premium pricing—industry reports show clinical tech outsourcing grew 12% in 2024 and vendor consolidation raised switching costs by ~20%. ICON mitigates this by signing multi-year alliances and volume contracts to lock pricing and secure 24\/7 support, cutting incident-driven delays 30% in recent programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Sources for High-Quality Real World Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe shift to real-world evidence (RWE) has raised demand for high-quality health data; vendors with large longitudinal datasets command premiums—some data licenses rose 15–30% in 2024—pressuring CRO margins.\u003c\/p\u003e\n\u003cp\u003eICON (Ireland) must negotiate access and revenue-share terms with these few data owners to keep its analytics platforms competitively priced and insightful for Pharma clients.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew suppliers control rich RWD—concentration risk\u003c\/li\u003e\n\u003cli\u003eData-license price growth ~15–30% (2024)\u003c\/li\u003e\n\u003cli\u003ePremium access boosts CRO value proposition\u003c\/li\u003e\n\u003cli\u003eNegotiation on pricing, exclusivity, and revenue share is critical\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Laboratory Supply Chain Sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProcurement of specialized lab equipment and cold-chain logistics is critical for ICON’s central labs; in 2024 ICON spent an estimated $120–150m on lab ops and logistics, so supplier price shocks directly cut margins.\u003c\/p\u003e\n\u003cp\u003eICON’s scale lets it negotiate bulk agreements with DHL, FedEx and Thermo Fisher, but reliance on specialized vendors means a single 10–15% price rise in cold-chain or reagents can reduce segment EBITDA by ~2–3%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh dependence on cold-chain: ~30% of lab costs\u003c\/li\u003e\n\u003cli\u003eTop vendors concentrated: 3–5 suppliers for key reagents\u003c\/li\u003e\n\u003cli\u003eBulk contracts reduce but don’t eliminate 10–15% price shock risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTalent shortages, site reliance \u0026amp; price shocks squeeze CRO margins—EBITDA down 2–3%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers wield moderate-to-high power: skilled CRAs\/data scientists (18–22% talent gaps) and site networks (sites supply \u0026gt;80% enrollments) push costs up; ICON’s Accellacare (1,200 sites) cuts dependence but 40–50% external site use remains. Tech and RWD vendors raised prices 12–30% in 2024, and 10–15% cold-chain shocks can cut lab-segment EBITDA ~2–3%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRA shortfall\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData scientist gap\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccellacare sites\u003c\/td\u003e\n\u003ctd\u003e1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExternal site reliance\u003c\/td\u003e\n\u003ctd\u003e40–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTech\/RWD price rise\u003c\/td\u003e\n\u003ctd\u003e12–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain shock impact\u003c\/td\u003e\n\u003ctd\u003eEBITDA −2–3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for ICON (Ireland) that uncovers competitive drivers, supplier and buyer power, threats from entrants and substitutes, and strategic barriers protecting incumbency, with actionable insights to inform investor materials and internal strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, one-sheet Porter's Five Forces summary for ICON (Ireland) that highlights competitive pressures and regulatory risks—ideal for fast, board-ready decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Large Pharmaceutical Clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa substantial portion of icon revenue per company filings from a small set top-tier pharma clients giving those buyers outsized negotiating leverage.\u003e\n\u003cpthese clients routinely secure volume-based discounts and bespoke service-level agreements tied to multi-year contracts pressuring fee rates scope margins.\u003e\n\u003cpicon must weigh the strategic benefit of anchor tenants against margin compression: a percentage-point ebitda hit is plausible if discounting intensifies.\u003e\n\u003c\/picon\u003e\u003c\/pthese\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRise of Funding-Sensitive Biotech Firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSmall and mid-sized biotech clients now make up ~35% of CRO demand but are funding-sensitive: 2024 VC biotech funding fell 28% to $18.6bn globally, raising pause\/cancel risk if rounds slip or trial readouts underperform. ICON must offer modular, scalable contracts and milestone pricing to win this cohort while hedging revenue exposure—for example, flex caps, phased scope, and short payment cycles to manage R\u0026amp;D spend volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Costs Associated with Switching CROs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOnce a trial starts, switching CROs is often cost-prohibitive due to data transfer, regulatory re-submissions, and site retraining—industry estimates put operational switch costs at 5–15% of a mid-size Phase III budget (roughly $5m–$15m on a $100m trial), giving ICON measurable protection against mid-project churn.\u003c\/p\u003e\n\u003cp\u003eStill, at contract award ICON faces strong buyer bargaining: global CRO RFP win rates hover ~10–20% and top-5 sponsors drive ~60% of bid volume, so competitive bidding at trial start keeps customer power high for new engagements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePerformance-Based Contracting and KPIs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpmodern drug developers push outcome-based contracts tying payments to milestones and recruitment targets shifting financial risk icon industry data show of major cro deals in included at least one outcomes clause raising potential penalty exposure into the tens millions for late or missed milestones.\u003e\n\u003cpconsequently clients leverage kpis to control trial execution demanding real-time reporting and triggering service-level penalties that compress icon margins increase cash-flow volatility.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003e28% of major CRO deals (2024) included outcomes clauses\u003c\/li\u003e\u003cli\u003ePenalties can reach into tens of millions per program\u003c\/li\u003e\u003cli\u003eKPI clauses increase margin pressure and cash-flow risk\u003c\/li\u003e\n\u003c\/pconsequently\u003e\u003c\/pmodern\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for End-to-End Strategic Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDemand is shifting from transactional outsourcing to integrated strategic partnerships, with top pharma clients seeking CROs that cover discovery to commercialization; in 2024, 62% of large biopharma preferred single-provider relationships, per industry surveys.\u003c\/p\u003e\n\u003cp\u003eConsolidation of services with ICON (market cap ~7.8bn USD in 2024) lets customers centralize oversight and negotiate better portfolio-wide terms, increasing bargaining power.\u003c\/p\u003e\n\u003cp\u003eBulleted summary:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% large biopharma prefer single-provider 2024\u003c\/li\u003e\n\u003cli\u003eICON ~7.8bn USD market cap 2024\u003c\/li\u003e\n\u003cli\u003eConsolidation → stronger price\/term negotiation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eICON under sponsor pricing pressure: top-client concentration, outcome fees, slim margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eICON faces high customer bargaining: ~35% revenue from top pharma (2024), 62% of large biopharma prefer single-provider deals, and 28% of major CRO contracts included outcome clauses in 2024—driving fee pressure, KPI penalties, and potential 1–3 ppt EBITDA hits; switching costs (5–15% of Phase III budgets) limit churn but intense RFP competition (10–20% win rates) keeps pricing power with sponsors.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-client revenue\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle-provider preference\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutcome-clause deals\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase III switch cost\u003c\/td\u003e\n\u003ctd\u003e5–15% ($5m–$15m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eICON (Ireland) Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact ICON (Ireland) Porter's Five Forces analysis you'll receive immediately after purchase—fully formatted, professionally written, and ready to download with no placeholders or samples.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746892394873,"sku":"iconplc-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/iconplc-five-forces-analysis.png?v=1772192902","url":"https:\/\/growthsharematrix.com\/products\/iconplc-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}